NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
November 23 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focusing on commercializing Avenova® for the
eye care market, announces the signing of an agreement with Paragon
Care Group Australia Pty Ltd for the exclusive distribution of
Avenova in Australia. Paragon Care Group will begin distributing
Avenova directly to consumers under its Designs For Vision brand
beginning in early 2021.
“We are delighted to expand the geographic reach of Avenova with
this agreement covering Australia,” said Justin Hall, NovaBay CEO.
“In Designs for Vision we have secured an ideal partner with a
reputation for sourcing the highest quality products and an
established market presence from more than 40 years of serving the
ophthalmology and optometry sectors in Australia.”
“Avenova fits extremely well with our portfolio of eye care
products,” said Nikolas Apostolou, General Manager of Designs for
Vision. “It is the only commercially available pure hypochlorous
acid lid and lash spray proven to be effective in eliminating the
underlying cause of bacterial dry eye, yet Avenova is soothing,
safe and effective for long-term use. We believe these qualities
make Avenova the best product to treat the chronic bacterial
infections that affect approximately 85% of all dry eye sufferers.
We are thrilled to make this product available to Australians with
dry eye disease.”
Avenova previously received approval from the Australian
Government Department of Health and was provided an Australian
Register of Therapeutic Good Certificate for distribution in that
country.
About Paragon Care Group Australia Pty Ltd
Paragon Care has become recognized as a leading provider of
equipment, devices and consumables to the healthcare market. We
also offer equipment repair, maintenance and total equipment
management through Paragon Care Service & Technology. Our
agility and experience enable customers to provide the right
solution to achieve the optimal outcome, today.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements about our success in selling Avenova in
Australia and generally the Company’s expected future financial
results. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those
expressed in or implied by the forward-looking statements. Factors
that might cause or contribute to such differences include, but are
not limited to, risks and uncertainties relating to our ability to
enter into the beauty market, find and maintain distribution
channels, and generally all risks associated with launching a new
product into the beauty industry. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201123005672/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2024 to Oct 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Oct 2023 to Oct 2024